0001104659-20-068501.txt : 20200601 0001104659-20-068501.hdr.sgml : 20200601 20200601173204 ACCESSION NUMBER: 0001104659-20-068501 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200601 FILED AS OF DATE: 20200601 DATE AS OF CHANGE: 20200601 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lindborg Stacy CENTRAL INDEX KEY: 0001813667 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36641 FILM NUMBER: 20934876 MAIL ADDRESS: STREET 1: C/O BRAINSTORM CELL THERAPEUTICS, INC. STREET 2: 1325 AVENUE OF AMERICAS, 28TH FLR. CITY: NEW YORK STATE: NY ZIP: 10019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC. CENTRAL INDEX KEY: 0001137883 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 207273918 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1325 AVENUE OF AMERICAS STREET 2: 28TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 201-488-0460 MAIL ADDRESS: STREET 1: 1325 AVENUE OF AMERICAS STREET 2: 28TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: BRAINSTORM CELL THERAPEUTICS INC DATE OF NAME CHANGE: 20041122 FORMER COMPANY: FORMER CONFORMED NAME: GOLDEN HAND RESOURCES INC DATE OF NAME CHANGE: 20030827 FORMER COMPANY: FORMER CONFORMED NAME: WIZBANG TECHNOLOGIES INC DATE OF NAME CHANGE: 20010409 4 1 tm2021119-2_4.xml OWNERSHIP DOCUMENT X0306 4 2020-06-01 0 0001137883 BRAINSTORM CELL THERAPEUTICS INC. BCLI 0001813667 Lindborg Stacy C/O BRAINSTORM CELL THERAPEUTICS INC. 1325 AVENUE OF AMERICAS, 28TH FLOOR NEW YORK NY 10019 0 1 0 0 EVP, Head Global Clin Research Common Stock 2020-06-01 4 A 0 25000 0 A 25000 D Stock Option (right to buy) 7.67 2020-06-01 4 A 0 100000 0 A 2021-02-28 2030-06-01 Common Stock 100000 100000 D Shares acquired are shares of restricted stock awarded on June 1, 2020 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 100% of the award on December 31, 2020, provided that the Reporting Person remains continuously employed by Issuer from the date of grant through the vesting date. The option, awarded on June 1, 2020 under the Issuer's 2014 Stock Incentive Plan, shall vest and become exercisable as to 50,000 of the underlying shares on February 28, 2021 ("First Vesting Date"), and the remaining 50,000 shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter until fully vested and exercisable on the second anniversary of the First Vesting Date, provided Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date. /s/ Nathaniel Gaede (Pursuant to Power of Attorney) 2020-06-01